Back to compounds

COMPOUND PROFILE / SMALL MOLECULES

Anamorelin.

Research draft

Anamorelin is an oral ghrelin-receptor agonist investigated for cancer-associated cachexia.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Anamorelin is an oral ghrelin-receptor agonist investigated for cancer-associated cachexia.

CLASSIFICATIONSmall molecules
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It affects appetite and endocrine pathways relevant to lean mass.

Human research

Randomised cancer trials measured appetite, weight and body-composition outcomes. Lean-mass changes do not guarantee improved strength.

Preclinical & other research

Animal work supports an appetite and metabolic rationale.

Safety & unknowns

Glucose, cardiac and other product-specific risks need the relevant prescribing information.

Regulatory status

Medical use is jurisdiction-specific; Japanese authorisation does not imply universal approval or enhancement eligibility.

Reported use & evidence

Research profile draft

The supplied Anamorelin profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds